Strategic Pipeline

Six molecules. Four therapeutic areas. The next three years.

LHC's 2026–2028 pipeline pairs strategic manufacturer partnerships with SAHPRA's ICH reliance pathway to bring oncology biosimilars, the latest HIV PrEP, affordable semaglutide, and a recombinant HPV vaccine to the South African market, at price points the National Health Insurance fund can underwrite.